← Evidence map

ArticleDermatology and therapy2026

Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis).

Luca Potestio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis). | OpenQuestion